Biopharmaceutical company Rock Holding Corporation (Nasdaq:SRRK) said on Tuesday that it plans to issue and sell USD150m shares of its common stock an underwritten public offering.
The company intends to provide the underwriters with a 30-day option to purchase up to an additional USD22,500,000 of shares of common stock offered in the public offering.
Net proceeds may be used by the company to advance SRK-015 in Spinal Muscular Atrophy, including costs associated with preparing for and executing clinical trials, including a Phase 3 clinical trial, SRK-181 in cancer immunotherapy, development of its preclinical and discovery programs, as well as for working capital and other general corporate purposes.
Subject to market and other conditions, there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms. JP Morgan Securities LLC, Jefferies LLC and Credit Suisse Securities (USA) LLC are the joint book-running managers.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval